ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025

ImPact Biotech announced that it will present interim data from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with low-grade upper tract...
Home/KnloSights/Clinical Trial Updates/ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025